HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure

Immunity
Peter D Kwong, John R Mascola

Abstract

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion surface. Antibodies isolated from HIV-1-infected donors, however, have been shown to recognize all major exposed regions of the prefusion-closed Env trimer, and an emerging understanding of the immunological and structural characteristics of these antibodies and the epitopes they recognize is enabling new approaches to vaccine design. Antibody lineage-based design creates immunogens that activate the naive ancestor-B cell of a target antibody lineage and that mature intermediate-B cells toward effective neutralization, with proof of principle achieved with select HIV-1-neutralizing antibody lineages in human-gene knock-in mouse models. Epitope-based vaccine design involves the engineering of sites of Env vulnerability as defined by the recognition of broadly neutralizing antibodies, with cross-reactive neutralizing antibodies elicited in animal models. Both epitope-based and antibody lineage-based HIV-1 vaccine approaches are being readied for human clinical trials.

Citations

Feb 15, 2019·Nature Communications·Qingbo LiuPaolo Lusso
Apr 18, 2019·Current Opinion in HIV and AIDS·Nicole A Doria-Rose, Elise Landais
May 10, 2019·Journal of Virology·Christoph H FellingerMichael Farzan
Nov 2, 2019·Science Translational Medicine·Barton F HaynesJohn R Mascola
Sep 5, 2019·Vaccines·Behazine CombadièreVincent Vieillard
Dec 7, 2019·Science·Amanda Agazio, Raul M Torres
Dec 21, 2019·Frontiers of Medicine·Qian Wang, Linqi Zhang
Oct 5, 2019·Human Vaccines & Immunotherapeutics·Bette Korber, Will Fischer
Oct 28, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert W EisingerAnthony S Fauci
Apr 13, 2019·The Journal of Experimental Medicine·Harald HartwegerMichel C Nussenzweig
Jul 28, 2019·The Journal of Experimental Medicine·Pia DosenovicAndrew T McGuire
Jul 28, 2019·The Journal of Experimental Medicine·Tara BancroftJustin J Taylor
Sep 28, 2018·Nature·Pilar MendozaMichel C Nussenzweig
Apr 26, 2019·Journal of Immunology Research·Karim DorghamVincent Vieillard
Jul 28, 2019·Vaccines·Karl SteficFrancis Barin
Nov 28, 2019·Nature Communications·Lei ZhangMichael B Zwick
Jun 11, 2020·Science Advances·Robyn L StanfieldVaughn V Smider
Jun 14, 2019·PLoS Pathogens·Panpan ZhouLinqi Zhang
May 31, 2019·Nature·Amelia EscolanoMichel C Nussenzweig
Jan 11, 2020·Frontiers in Immunology·Bin SuChristiane Moog
Aug 10, 2019·Frontiers in Immunology·Jim Boonyaratanakornkit, Justin J Taylor
Apr 4, 2020·Emerging Microbes & Infections·Qian WangLinqi Zhang
Oct 20, 2018·Nature Immunology·Devin Sok, Dennis R Burton
Aug 30, 2018·Frontiers in Immunology·Chaim A Schramm, Daniel C Douek
Jul 26, 2019·Science Translational Medicine·Matthew R GardnerMichael Farzan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.